Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Promotes anchorage-independent cell growth and tumor formation (By similarity). Additionally we are shipping KIAA1524 Kits (7) and KIAA1524 Proteins (4) and many more products for this protein.
Showing 10 out of 62 products:
Human Monoclonal KIAA1524 Primary Antibody for FACS, ICC - ABIN258615
Soo Hoo, Zhang, Chan: Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. in Oncogene 2002
Show all 10 references for ABIN258615
Human Polyclonal KIAA1524 Primary Antibody for ICC, IF - ABIN261179
Pallai, Bhaskar, Sodi, Rice: Ets1 and Elk1 transcription factors regulate cancerous inhibitor of protein phosphatase 2A expression in cervical and endometrial carcinoma cells. in Transcription 2013
Show all 9 references for ABIN261179
Human Polyclonal KIAA1524 Primary Antibody for FACS, ICC - ABIN261740
Kerosuo, Fox, Perälä, Ahlqvist, Suomalainen, Westermarck, Sariola, Wartiovaara: CIP2A increases self-renewal and is linked to Myc in neural progenitor cells. in Differentiation; research in biological diversity 2010
Show all 8 references for ABIN261740
CIP2A is upregulated in MM, and CIP2A expression promotes cell proliferation and clonogenic formation ability by regulating the expression of AKT (show AKT1 Antibodies) phosphorylation and c-Myc (show MYC Antibodies).
Gambogenic acid is a CIP2A inhibitor that interferes with the ubiquitination and destabilization of CIP2A.
Silencing CIP2A enhanced CuB-induced growth inhibition.
CIP2A copy number increase is associated with poor patient survival in human HNSCC.
These results indicate that CIP2A modulates myeloma cell proliferation and apoptosis via PI3K (show PIK3CA Antibodies)/AKT (show AKT1 Antibodies)/mTOR (show FRAP1 Antibodies) signaling and suggest that it can potentially serve as a drug target for the treatment of multiple myeloma.
CIP2A is involved in regulating multidrug resistance of cervical adenocarcinoma.
These results suggest that CIP2A is involved in tumor progression in bladder cancer
patients with a stronger expression of CIP2A in tgastric umor tissues had no significant relationship with these genes that are related to gastric cancer chemotherapy drug resistance
CIP2A levels were significantly associated with the American Joint Committee on Cancer (AJCC) stage, histological grade and lymph node metastasis in breast cancer patients.
CIP2A is a tumor-associated autoantigen in lung cancer, which promote lung cancer proliferation partially through MKK4 (show MAP2K4 Antibodies)/7-JNK (show MAPK8 Antibodies) signaling pathway.
Knockdown of CIP2A by stable CIP2A siRNA transfection inhibited MDA-MB-231 cell proliferation, invasion, colony growth in vitro, and xenograft growth and metastasis in vivo of breast cancer in mice.
CIP2A as a hitherto unrecognized mediator of T-cell activation.
Downregulation of CIP2A suppresses cell proliferation and growth of nasopharyngeal carcinoma.
CIP2A strongly interacts with NEK2 (show NEK2 Antibodies) during G2/M phase, thereby enhancing NEK2 kinase (show NEK2 Antibodies) activity to facilitate centrosome separation in a PP1 (show PPP1CC Antibodies)- and PP2A (show PPP2R2B Antibodies)-independent manner.
Data show that CIP2A expression can be systematically inhibited without severe consequences to normal mouse development and viability may have clinical relevance regarding targeting of oncogenic CIP2A for future cancer therapies.
Loss of CIP2A in Myc (show MYC Antibodies)-overexpressing neural progenitor cells significantly reduces the ability of Myc (show MYC Antibodies) to increase self-renewal and proliferation.
Promotes anchorage-independent cell growth and tumor formation (By similarity).
protein CIP2A homolog
, CONSTANS interacting protein 2a
, hypothetical protein LOC100216050
, cancerous inhibitor of PP2A
, p90 autoantigen
, protein CIP2A
, p90 autoantigen homolog